Search
All Clinical Trials
A listing of 24274 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 24274
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients
Recruiting
This pilot phase II trial studies how well selinexor works when given together with induction, consolidation, and maintenance therapy in treating older patients with acute myeloid leukemia. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and daunorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina +1 locations
Conditions: Untreated Adult Acute Myeloid Leukemia
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Recruiting
This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in people with untreated cholangiocarcinoma that cannot be removed with surgery. The researchers want to find out whether the study treatment works better than the standard chemotherapy to delay progression of disease. For the study treatment to be considered better than the standard treatment, the study tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: National Heart, Lung, and Blood Institute (NIH) (Data Collection Only), Bethesda, Maryland +10 locations
Conditions: Intrahepatic Cholangiocarcinoma
Collection of Clinical Data and Specimens for Research in Hearing, Balance, Taste, Smell, Voice, Speech, and Language Disorders.
Recruiting
Background:
People with hearing, balance, and taste, smell, voice, speech, language, and other Ear, Nose, and Throat (ENT) disorders may seek treatment at the National Institute on Deafness and Other Communication Disorders (NIDCD). Some of these people may benefit from enrolling in the NIDCD intramural research program to receive their care. Enrolling will also allow investigators to collect participants clinical data and specimens for future research.
Objective:
This natural history study h... Read More
Gender:
ALL
Ages:
Between 2 years and 99 years
Trial Updated:
03/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hearing Loss, Deafness
Tocilizumab in Lung Transplantation
Recruiting
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids).
The primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance i... Read More
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
03/20/2025
Locations: St. Joseph's Hospital and Medical Center (Site #: 71192), Phoenix, Arizona +14 locations
Conditions: Lung Transplant
Natural History of Depression, Bipolar Disorder and Suicide Risk
Recruiting
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medica... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults
Recruiting
The study is designed to evaluate the safety, immunogenicity, and efficacy of the intramuscular administration of a CS6 based vaccine (CssBA) against ETEC co-administered with double mutant labile toxin (dmLT) in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. Approximately 72 adult participants, divided into 4 cohorts of 18, will be randomized 1:1 to receive vaccine (45 micrograms CssBA with 0.5 micrograms dmLT) or placebo (normal saline) on... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
03/20/2025
Locations: University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland +1 locations
Conditions: Escherichia Infection
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Recruiting
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer).
The body has different ways of fighting infection and disease. No one way seems perfect for fighting cancers. This research combines two different ways of fighting disease, antibodies and T cells. Antibodies are proteins that protect the body from bacterial and other diseases. T cells, or T lymphocytes, are special infection-fighting blood cells that can kill other cells includi... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
03/20/2025
Locations: Houston Methodist Hospital, Houston, Texas +1 locations
Conditions: T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Recruiting
Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesenchymal origin, notably sarcoma and mesothelioma, FAP expression has also been observed on the tumor cells themselves. Given the restricted expression profile, FAP is a promising target for peptide-target... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +8 locations
Conditions: Solid Tumor
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
Recruiting
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: University of Alabama at Birmingham (UAB), Birmingham, Alabama +57 locations
Conditions: Advanced Non-Small Cell Lung Cancer
A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
Recruiting
Hot flashes and night sweats (also known as vasomotor symptoms or VMS) are the most common symptoms which bother women in menopause. This study will follow women going through menopause who have hot flashes and night sweats that cause them bother. They will be starting a non-hormonal therapy prescribed by their healthcare provider (HCP) to treat these symptoms. The women will visit their HCP's office, research center, or both. They will receive prescriptions for the non-hormonal therapy from the... Read More
Gender:
FEMALE
Ages:
Between 40 years and 75 years
Trial Updated:
03/20/2025
Locations: Alabama Clinical Therapeutics, Birmingham, Alabama +60 locations
Conditions: Hot Flashes
Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+)
Recruiting
Although global efforts have been made to end the HIV epidemic, there are still some gaps in HIV testing, antiretroviral therapy (ART) adherence, and viral suppression (VS) among people with HIV (PWH). These gaps are particularly prominent in the Deep South of the United States (US), where PWH face challenges in accessing healthcare services. In response, a team of experienced researchers has developed and tested the Community Health Workers And MHealth to ImProve Viral Suppression (CHAMPS) inte... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Health Services Center, Inc., Hobson City, Alabama +3 locations
Conditions: HIV/AIDS
A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Recruiting
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE.
Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward.
Patient questionnaires will measure... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/20/2025
Locations: Rocky Mountain Gastroenterology, Littleton, Colorado +9 locations
Conditions: Eosinophilic Esophagitis (EoE)
1 - 12 of 24274